文献速递慢性肾脏病

美国CKD患病率全国估计及去除eGFR种族调整的潜在影响

National Estimates of CKD Prevalence and Potential Impact of Estimating Glomerular Filtration Rate Without Race.
PubMed 文献 · J Am Soc Nephrol · 2021-05-06

该研究基于NHANES 2015-2016和VA 2015数据,评估去除CKD-EPI eGFR方程种族调整对CKD患病率、药物剂量调整和肾衰竭风险预测的影响。结果显示黑人成人CKD患病率在NHANES从5.2%升至10.6%,VA队列从12.4%升至21.6%,并影响多种药物剂量决策。去除种族调整后肾衰竭风险方程判别力仍高且校准略有改善。

要点

  • 去除种族调整使黑人CKD患病率约翻倍。
  • 大量黑人患者eGFR重分类影响药物剂量调整。
  • 肾衰竭风险方程判别力仍高且校准略改善。

核心结论

  • 去除CKD-EPI eGFR种族调整将使美国黑人成人CKD估计患病率翻倍,并影响大量药物剂量决策,但可能改善高风险黑人肾衰竭风险预测准确性。

研究设计与样本

  • 横断面和纵向分析,使用2015-2016年NHANES≥18岁成人及2015年VA医疗系统数据。

主要发现

  • NHANES黑人CKD患病率从5.2%升至10.6%,VA队列从12.4%升至21.6%。
  • 黑人退伍军人中加巴喷丁使用者41.0%、环丙沙星33.5%、二甲双胍24.0%、阿替洛尔6.9%、瑞舒伐他汀6.6%、曲马多5.8%被重分类至更低eGFR需调整剂量或停药。
  • 去除种族调整后肾衰竭风险方程在黑人中判别力仍高,校准总体略改善,高预测风险水平校准更好。

临床怎么用

  • 临床采用无种族调整eGFR时需重新评估黑人患者CKD患病率及药物剂量,并关注肾衰竭风险预测变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The implications of removing the adjustment for Black race in equations to eGFR on the prevalence of CKD and management strategies are incompletely understood. METHODS: We estimated changes in CKD prevalence and the potential effect on therapeutic drug prescriptions and prediction of kidney failure if race adjustment were removed from the CKD-EPI GFR estimating equation. We used cross-sectional and longitudinal data from adults aged ≥18 years in the National Health and Nutrition Examination Survey (NHANES) from 2015 to 2016, and the Veterans Affairs (VA) Health Care System in 2015. In the VA cohort, we assessed use of common medications that require dose adjustment on the basis of kidney function, and compared the prognostic accuracy of the Kidney Failure Risk Equation with versus without race adjustment of eGFR. RESULTS: The prevalence of CKD among Black adults increased from 5.2% to 10.6% in NHANES, and from 12.4% to 21.6% in the VA cohort after eliminating race adjustment. Among Black veterans, 41.0% of gabapentin users, 33.5% of ciprofloxacin users, 24.0% of metformin users, 6.9% of atenolol users, 6.6% of rosuvastatin users, and 5.8% of tramadol users were reclassified to a lower eGFR for which dose adjustment or discontinuation is recommended. Without race adjustment of eGFR, discrimination of the Kidney Failure Risk Equation among Black adults remained high and calibration was marginally improved overall, with better calibration at higher levels of predicted risk. CONCLUSIONS: Removal of race adjustment from CKD-EPI eGFR would double the estimated prevalence of CKD among Black adults in the United States. Such a change is likely to affect a sizeable number of drug-dosing decisions. It may also improve the accuracy of kidney failure risk prediction among higher-risk Black adults.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Duggal V, Thomas IC, Montez-Rath ME, et al. National Estimates of CKD Prevalence and Potential Impact of Estimating Glomerular Filtration Rate Without Race. J Am Soc Nephrol. 2021. PMID: 33958490. doi:10.1681/ASN.2020121780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。